comparemela.com
Home
Live Updates
Elixir Medical's Late-Breaking 12-Month Data Demonstrate Sig
Elixir Medical's Late-Breaking 12-Month Data Demonstrate Sig
Elixir Medical's Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World's First Site-Specific Antithrombotic Therapeutic Compared to DES
DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months
Related Keywords
New Zealand ,
Sao Paulo ,
Sãpaulo ,
Brazil ,
Paris ,
France General ,
France ,
United States ,
Alexandran Nowbar ,
Jamesp Howard ,
Michael Foley ,
Kui Hong ,
Motasim Sirhan ,
Xiaoqing Li ,
Liza Chacko ,
Darrelp Francis ,
Ochen ,
Dina Mahdi ,
Sayan Sen ,
Alexandre Abizaid ,
Graham Cole ,
Rasha Al Lamee ,
Yuhao Su ,
Yousif Ahmad ,
Christopher Kane ,
Christopher Rajkumar ,
Centers For Disease ,
Randomized Controlled Trial ,
Randomized Clinical Trial ,
Triple Drug Eluting Coronary Implant ,
Eluting Coronary Stent System ,
Disease Facts ,
Disease Control ,
Matthew Shun Shin ,
Percutaneous Coronary Intervention ,
Myocardial Infarction Stratified ,
Unstable Coronary Artery Disease ,
Randomized Controlled Trials ,
Cardiovascular Quality ,
Non Cardiac Surgery Early ,
Percutaneous Coronary ,